Trial Profile
A Study of Fixed-Dose Rate Gemcitabine, Cisplatin, and Bevacizumab in Previously Untreated Patients With Metastatic Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 01 Apr 2008 Results published in Invest New Drugs 1 Apr 2008 [Epub ahead of print].
- 06 Nov 2007 Status change from recruiting to in progress
- 15 Dec 2005 New trial record.